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Mycobacteria strains belonging to the Mycobacterium tuberculosis complex were isolated from
seals found in the South Atlantic. The animals were received in Mundo Marino installations and
treated for Mycobacterium tuberculosis complex by conventional therapy of intensive care and
enriched food supply; however, in all cases treatment failed. Necropsies of all animals revealed
extensive lesions compatible with tuberculosis involving lungs, liver, spleen and lymphatic
nodes. Classical biochemical methods as well as molecular techniques using the IS6110 probes
were performed for mycobacterial identification. Furthermore, the LCx M. tuberculosis assay
(Abbott Laboratories) identified all strains as Mycobacterium tuberculosis complex members.
The in vitro susceptibility pattern was examined in mycobacterial strains isolated from seven
seals and in 3 reference strains - BCG, H37Rv (M. tuberculosis) and AN5 (Mycobacterium
bovis) - to 4 medications - isoniazid, rifampin, streptomycin and ethambutol. Minimal inhibitory
drug concentrations were determined by the Mycobacterial Growth Indicator Tube (BD Argentina)
method and a microdilution and colorimetric assay using 3-(4-5 dimethyltiazol-2)-2,5
diphenyltetrazolium bromide. All the isolates and the reference strains BCG and AN5 were
inhibited by MIC values similar to those of H37Rv with good agreement obtained by both
techniques. These findings suggest that a therapeutic regimen aimed to seals diagnosed with
tuberculosis play an important role in the prevention of tuberculosis transmission from infected
animals to humans that are in routine contact with them.
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Susceptibilidad in vitro a los medicamentos anti-tuberculosos de aislados de cepas del
complejo Mycobacterium tuberculosis obtenidos a partir de lobos marinos
Se han hallado cepas de micobacterias aisladas de lobos marinos del Atlántico sur y pertenecen
al complejo de Mycobacterium tuberculosis. Los animales se recibieron en las instalaciones
del Oceanario Mundo Marino y fueron tratados apropiadamente para su recuperación con la
terapia convencional, cuidados intensivos y suplemento alimentario pero no se observó mejoría
en su estado general. Se practicaron necropsias en todos los animales y se observaron lesiones
extensas compatibles con tuberculosis en pulmones, hígado, bazo y ganglios linfáticos. Para
la identificación de las micobacterias, se realizaron pruebas bioquímicas y técnicas de biología
molecular con la sonda IS6110. Además, se identificaron todas las cepas como pertenecientes
al complejo M. tuberculosis mediante el equipo LCx M. tuberculosis Assay (Abbott Laboratories).
El objetivo de este estudio fue determinar in vitro la sensibilidad de las cepas patrón BCG,
H37Rv (M. tuberculosis) y AN5 (Mycobacterium bovis) y la de las siete aisladas de lobos
marinos a isoniacida, rifampicina, estreptomicina y etambutol. La concentración inhibitoria
mínima (CIM) de las drogas antituberculosas se llevó a cabo con el equipo Mycobacterial
Growth Indicator Tube (MGIT, BD, Argentina) y la microdilución con el ensayo colorimétrico con
bromuro de 3-(4-5 dimetiltiazol-2)-2,5 difeniltetrazolio. Todos los aislamientos y las cepas de
referencia BCG y AN5 se inhibieron con valores CIM de los de H37Rv con buena concordancia
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entre los resultados obtenidos con ambas técnicas. Los hallazgos permiten sugerir que podrían
ser una importante ayuda terapéutica en los lobos marinos con diagnóstico de tuberculosis y
evaluar el posible papel sanitario en la prevención y transmisión de la tuberculosis de los
animales a los humanos y el trabajo en conjunto.
Palabras clave: lobos marinos, tuberculosis, análisis de la sensibilidad in vitro
Tuberculosis (TB) continues being an important
sanitary problem worldwide in human and animal
health (1-3). In Argentina, TB incidence rate was
of  35.5 per 100,000 inhabitants in 1997. Bovine
population is estimated in almost 60 million, being
2.4 mill ion (4.0%) of them infected with
Mycobacterium bovis. Previous studies of genetic
characterisation using IS6110 probes have
demonstrated that the mycobacterial strains
isolated from seals belong to the Mycobacterium
tuberculosis complex (MTB) which consists of
Mycobacterium tuberculosis, Mycobacterium
microti, Mycobacterium bovis, Mycobacterium
africanum and bacillus of Calmette and Guerin
(BCG) species; more recently, three novel strains
has been described: Mycobacterium canettii, My-
cobacterium caprae and Mycobacterium pinnipedii
sp. nov. (4-7). Seal mycobacterial  isolates were
found in the South Atlantic Ocean shores and they
died at the Foundation of Mundo Marino
installations (8-11). Since MTB are higly related
phylogenetic species, it is reasonable to think that
the antibiotics active against the rest of the
species belonging to the complex, could effec-
tively inhibit seal mycobacteria.
The aim of this study was to determine the in vitro
activity against seal mycobacteria of the
antibiotics currently used for treating TB in humans
(12,13). Besides, the possible role of these drugs
in a future therapeutic scheme to prevent TB
transmission among animals sharing their living
space and the human beings working with them,
could be further evaluated (14-16).
In 1993, there was a report of 3 cases of
tuberculosis in wild seals (1 New Zealand fur seal
and 2 Australian sea lions) found dead on the
southern coast of Western Australia. REA and
hybridisation studies with oligonucleotide and RNA
probes were performed to assess the similarity of
strains from the wild seals to the strain previously
isolated from seals at the marine park near Perth,
and from the seal trainer who had workerd with
the seals at the same marine park for 3 years.
One of the two wild sea lion strains appeared to
have identical DNA fragment patterns to the strains
from the captive seal and the seal trainer. The other
sea lion isolate showed minor difference with 1
endonucleases used. Differences in these isolates
were more clearly seen by RFLP after
hybridisation with 2 DNA probes. The wild seal
isolates and M. bovis also differed because the
wild seal isolates lacked detectable amounts of
MPB 70 antigen, using a monoclonal antibody
raised against MPB 70 antigen which is considered
to be species specific for M. bovis. The secretory
protein MPB 70 present in M. bovis was not
detected in the wild seal isolates using sodium
dodecyl sulphate polyacrylamide gel electro-
phoresis and Western blotting techniques. Analysis
of REA and RFLP patterns indicated that the seal
tuberculosis isolates were from a unique
genetically distinct cluster within the M.
tuberculosis complex.
There was a report of tuberculosis in 4 fur seals
(Arctrocephalus australis) and 1 sea lion (Otaria
flavescens) found dead or dying on the south
western Atlantic coast of Argentina. Genomic DNA
from all 5 mycobacterial isolates on Stonebrink
media was analysed by the RFLP technique. Using
the IS6110 probe, 4 of the isolates had identical
fingerprintings with bands of 7.8, 4.2, and 1.8 kbp.
The fifth  isolate only had the 4.4, 2, and 1.8 kbp
bands. These fingerprint patterns were different from
those of M.bovis strain isolated from Argentinian
cattle, which contained a unique 1.9 kbp band,
and also differed from those human M. tuberculo-
sis isolates which have many IS6110 copies.
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Materials and methods
Isolates
Seven mycobacteria isolated from seals that were
found in the South Atlantic shores
Reference strains: M. tuberculosis H37Rv (ATCC
27294), M. bovis BCG (Pasteur strain), and M.
bovis AN5.
All the mycobacteria were isolated in Stonebrink
solid medium (17,18) and they were identified as
part of the MTB by both biochemical and molecu-
lar techniques (17-19). In addition, LCx M. tuber-
culosis LCx a molecular, commercial and auto-
mated test (20), was used for strain identification.
Reagents
A solution of 5 mg/ml in water of 3-4 (4,5-
dimethylthiazolyl-2)-2,5-diphenyl tetrazolium bro-
mide (MTT), purchased from Sigma, was prepared
and, then, sterilised by Millipore 22 nm filters.
A solution of 20% Tween 80 (Sigma) in water was
prepared and later sterilised by autoclaving 20 min
at 1 atmosphere and 121°C (14,21).
All the mycobacteria were isolated in Stonebrink
solid medium (17,18) and they were identified as
part of the M. tuberculosis complex by both bio-
chemical and molecular techniques (17-19).
Middlebrook 7H9 liquid medium (M7H9, BD Ar-
gentina) supplemented by 10% OADC enrichment
(BD, Argentina) was used to prepare the different
bacterial solutions to be later inoculated in the
microdilution assay.
Mycobacteria growth indicator tubes (MGIT, BD
Argentina) supplemented by 10% OADC enrich-
ment were used to determine MIC values by the
macrodilution system.
Drug solutions
Antibiotics used for MIC determinations were: iso-
niazid (INH), streptomycin (SM), ethambutol
(EMB), and rifampin (RMP). The drugs were pur-
chased from Sigma (USA).
Stock solutions of each drug were made in water
for INH, SM, and EMB and dimethylformamide
(Sigma) for RMP.  Final working dilutions of each
drug were then prepared in M7H9.
Mycobacteria inocula
Mycobacterial suspension (S1) was prepared from
a pure culture in M7H9 liquid medium supple-
mented by OADC enrichment. Suspension A was
later adjusted for turbidity to the No. 1 McFarland
standard (~4 x 106-107 CFU/ml).
Mycobacteria working suspensions S2 and S3 to
be used in the MTT method were later prepared
by diluting S1, 1:25 (S2), 1:2,500 (S3, 1:100 from
S2) and 1:50 (S4) with M7H9.
Minimal inhibitory concentrations
The MIC of each drug was defined as the lowest
concentration that completely inhibited the in vitro
mycobacterial growth. Colorimetric microdilution
assay with MTT was used for MIC determinations.
Susceptibility testing of the isolates was made
by macrodilution method on MGIT system .Table
1 shows the concentration range of each drug
tested in this study by both of the systems used.
Determinations of colorimetric MIC
MTT assays were performed in 96 flat-bottom
microtiter plates (Falcon 3072, BD, Argentina); 200
µl of sterile deionized water was added to all outer-
perimeter wells to minimise evaporation of culture
medium during the incubation period. The wells in
row B to G in column 2 to 11 received 100 µl of
M7H9 broth. One hundred µl of a solution contain-
ing INH 4.00 µg/ml was added to wells 2B and 8B.
A solution of 8 µg/ml of RMP was added to wells
3B and 9B. Solutions containing 32 µg/ml of SM
and 128 ug/ml of EMB were put in wells 4B and
10B and 5B and 11 B, respectively.
Wells 6 and 7 C, D, and E were used as growth
control free of drugs, while wells 6 and 7 F were
used as diluted 1:100 growth control (GC) also
without drugs. Wells 6 B and 7 B were used as
medium control containing only 200 µl of M7H9.
This scheme was designed for both making the
tests and later obtaining duplicate results as well
as to study 2 different strains in the same assay
(see scheme 1) (22).
One hundred µl of S2 bacterial suspension were
added to the wells containing the appropriate
dilution of each drug and control. A volume of 100
µl of the bacterial suspension S3 was put into the
88
Biomédica 2004;24(Supl.):85-91BERNARDELLI A., MORCILLO N., LOUREIRO J., QUSE V., DAVENPORT S.
well 7 F used as diluted GC. The plates, placed in
plastic sealed bags were incubated at 37°C for 5
days and afterwards a mixture of 12 µl of Tween
80 and 10 µl of MTT prepared solutions were added
to one of the wells used as undiluted GC. The
plates were then incubated 24 hours more. If the
change of colour from yellow to dark blue or purple
was observed indicating mycobacterial growth, the
mix of Tween 80 and MTT was added to the rest
of the wells. After 24 hours of incubation under
the above-mentioned conditions, visual readings
were made and MIC were recorded. The
concentration of drug in the well showing less
change of colour than that of the 1:100 diluted GC
well, was considered to be the MIC value for the
assessed drug (23).
Macrodilution method of MGIT
Macrodilution MIC determination was performed
using the MGIT (supplemented by 10% OADC
enrichment) containing different drug
concentrations (table 1) and one free of them to
be used as GC. A volume of 0.5 ml of S4 bacterial
suspension was added to each MGIT to a final
volume of 5.0 ml. The tubes were later incubated
at 37°C for a total period of 15 days and daily
examined for fluorescence at 365 nm using a UV
transilluminator. The time in which the growth
control became positive was recorded. The drug
concentration in the MGIT in which no fluorescence
could be detected after the incubation time was
considered to be the MIC value for the tested drug.
The incubation of the MGIT was prolonged for 30
days if the tubes were negative.
Results
All the studied strains were identified as part of
MTB by the LCx M. tuberculosis assay.
As it was considered before, MIC was the lowest
concentration of each drug which inhibited more
than 99% of the original population growing in a
drug-free medium well (13). Table 2 shows the
isolates and the reference strains BCG and AN5,
inhibited by MIC values similar to those obtained
for H37Rv strain. Mean value of MICs obtained
by A-MTT were INH, 0.17 µg/ml (range: <0.03 µg/
ml to 0.25 µg/ml); SM, 1.7µg/ml (range: 0.80-4.00
µg/ml); RMP, 0.11µg/m (range: 0.10-0.50 µg/ml),
EMB, 6.00 µg/ml (range: >16.00- <2.00 µg/ml).
Good agreement among MIC values results from
the tested drugs obtained by both techniques was
also observed for each one of the isolates and
the reference strains (tables 1  and  2). MICs of
EMB showed bigger values than those found for
the rest of the drugs. Significant differences in
MICs by A-MTT and MGIT were observed for
EMB in the strain 1864. Nevertheless, MICs by
A-MTT and MGIT system were highly similar.
According to the results obtained for H37Rv, BCG
and AN5 reference strains with both methods, we
observed that the wild seal mycobacteria isolates
were susceptible in vitro to the antimicrobial agents
currently used in TB chemotherapy.
The microtiter system allowed determining the MIC
of the drugs at a very low price (almost US $4.00
for 2 tested strains) since the microtiter plate price,
which is the most expensive element in this assay,
is almost US $3.00 in our country.
Discussion
Both systems used in this study for in vitro MIC
determination, MGIT, which is a commercial
macrodilution system, and MTT the in-house
microdilution assay, contain the same culture liquid
Table 1. Concentration of the tested drugs used for MIC determination by the colorimetric MTT assay and the MGIT system.
Drug MTT MGIT
(µg/ml) (µg/ml)
Isoniazid (INH) 1.00-0.50-0.25-0.13-0.06-0.03 0.10-0.50
Streptomycin (SM) 8.00-4.00-2.00-1.00-0.50-0.25 0.80-2.00-4.00-8.00
Rifampin (RMP) 2.00-1.00-0.50-0.25-0.13-0.06 1.00-0.50
Ethambutol (EMB) 32.00-16.00-8.00-4.00-2.00-1.00 8.00-4.00-2.00
MTT: 3-(4-5 dimethyltiazol-2)-2,5 diphenyltetrazolium bromide
MGIT: mycobacterial growth indicator tube
89
Biomédica 2004;24(Supl.):85-91 IN VITRO SUSCEPTIBILITY TESTING OF MYCOBACTERIUM TUBERCULOSIS
medium albeit they use different final volumes and
growth indicators. They were useful tools for
mycobacteria detection from pure cultures after a
short incubation period. Consequently, they
appeared to be suitable for determining in vitro
MIC of several antituberculosis drugs on the seal
mycobacteria isolates. While both of the
techniques were easy to set up in a clinical
laboratory, MGIT system was safer than the
microdilution MTT method. Albeit reagents used
for MTT method are cheaper than those for MGIT
system, the first one is much more laborious than
the last one. In addition, all the tested SB strains
were identified as members of M. tuberculosis
complex by the commercial LCx assay. These
facts are very important taking into account that
the affected animals have a commercial value and
also they are frequently living in special settings,
sharing their space with human trainers (24,25).
Transmission of seal mycobacteria organisms is
unknown, but it could be possible that people might
become infected by the airborne via as well with
these mycobacteria.
In vitro activity of the antibiotics currently used in
human TB chemotherapy against mycobacteria
isolated from seals was observed in this study. It
has suggested us the possibility to set up spe-
cific therapeutic schemes intended to improve the
animal health and also to diminish the transmis-
sion of seal mycobacteria among the members of
the community, as well as to the personnel in-
volved in their care. Additional efforts should be
made attempting to achieve the disease diagno-
sis and the seal mycobactera isolation from the
live seals  (13). Animals with clinical signs and
symptoms of the disease (like weight loss, nova
clinical symptom, abnormal behaviour) should be
properly examined in order to confirm the diagno-
sis of TB. Biopsies, mouth swabs, blood and exu-
dates from different lesions might be investigated
looking for mycobacteria by performing micros-
copy direct examination and cultures. Today no
antibiotic treatment has been tried in sea mam-
mals, so when the decision to start has been
made, periodic controls must be performed on the
animals in order to evaluate the outcomes related
to the proposals for these particular cases. Seals
with TB diagnosis could be handled according to
the currently used chemotherapy rules in human
beings in order to obtain preliminary results, which
could indicate needed changes to be made.
Briefly, the proposed therapy consists in the fol-
lowing phases:
- Two months long attack phase with 4 drugs:
INH at doses of 5 to 8 mg/kg dayly; RMP at 10
mg/kg dayly; SM at 15 to 12 mg/kg dayly, and
EMB at 15 to 25 mg/kg dayly.
- Four months long consolidation phase with 2
drugs: H and RMP at the above mentioned
doses.
All the antibiotics except SM, which has to be
injected, are administered by oral route.
Periodically, assessment of liver function and side
effects of the drugs administered to the animals
should be made. Furthermore, conclusions about
treatment length, doses and drug composition of
Table 2. MIC results obtained by the colorimetric MTT assay and the macrodilution MGIT system.
MTT MIC (µg/ml)  MIC MGIT (µg/ml)
Isolate INH SM RMP EMB INH SM RMP EMB
identification
1850 0.25 2.00 <0.06 8.00 0.25 2.00 0.10 8.00
1849 0.03 2.00 <0.06 <1.00 0.10 4.00 0.10 2.00
1868 0.25 2.00 <0.06 8.00 0.25 4.00 0.10 8.00
1864 0.06 0.50 0.13 <1.00 0.25 4.00 0.00 16.00
1337 0.25 2.00 0.25 2.00 0.25 2.00 1.00 2.00
2186 <0.03 0.50 0.13 <1.00 0.10 0.80 0.50 2.00
2192 <0.03 0.50 0.13 <1.00 0.10 0.80 0.50 2.00
H37Rv 0.13 1.00 <0.06 <1.00 0.10 0.80 0.50 2.00
BCG 0.13 2.00 <0.06 2.00 0.25 2.00 0.10 4.00
AN5 0.25 4.00 0.13 2.00 0.25 2.00 0.10 4.00
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the proposed regimens could be drawn out from
these observations.
The assistance to stranded sea mammals not
recovered due to an inadequate treatment lacking
tuberculostatic drugs will be achieved by TB
chemoprophilaxis.
New species typing by molecular biology probe
IS6110 and LCx M. tuberculosis assay (Abbott
Laboratories) as belonging to the M. tuberculosis
complex.
In vitro susceptibility has been observed towards
isoniazid, rifampicin, streptomycin, and
ethambutol by microdilution and colorimetric assay
with growth inhibition of all strains.
A sanitary role, this finding implies using the
results to prevent transmission on TB in humans
exposed due to their work activities: parks,
oceanariums, animal trainers veterinarians,
cleaning personnel and facilities maintenance staff
personnel that daily feed sea mammals
populations. The subspecies mentioned in this
work have pathogen characteristics since they
produce lesions spread in that animal that cause
mortality. All this implies a sanitary problem due
to the number of hours that trainers are in contact
with animals and in shows to the possibility of a
job-related disease, spread the disease among in-
contact animals and treatment to prevent a future
problem of zoonotic transmission.
Conclusion
MGIT and A-MTT microdilution techniques were
useful tools for determining in vitro MICs of several
antituberculosis drugs on seal mycobacteria
isolates and, therefore, they were in vitro inhibited
by them. These findings allowed us to suggest
that it could be helpful to assess a therapeutic
system aimed to treat seals with TB diagnosis.
The possible treatment should be based on that
for human beings regarding doses and adminis-
tration principles.
In the near future, it could be helpful to develop a
research project inoculating laboratory animals in
order to have experimental infections, which would
be further treated with antibiotic schemes including
the studied drugs.
Demonstration of the ethiological agent of the dis-
ease and the possibility to start, in a short time,
the adequate therapy, should be the weapons for
fighting against lives and economic losses caused
by this particular kind of TB.
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